CCS Pneumonia: CAP vs HAP vs VAP — Antibiotic Selection & Management

SEO Title: CCS Pneumonia Cases | CAP Antibiotics, HAP VAP Step 3 (2026)

Meta Description: Master CCS pneumonia: CURB-65 scoring, antibiotic selection by setting, cultures, de-escalation, and atypical organisms.

Target Keywords: CCS pneumonia management, CCS CAP antibiotics, CCS HAP VAP, step 3 CCS pneumonia

URL Slug: ccs-pneumonia-deep-dive

Opening

Pneumonia cases are staples on Step 3 CCS exams, testing your ability to rapidly risk-stratify severity, order blood and respiratory cultures before antibiotics, select empiric antimicrobials based on setting and patient factors, and de-escalate appropriately once susceptibilities return. Whether managing a 65-year-old with community-acquired pneumonia (CAP) in the clinic or a mechanically ventilated patient with ventilator-associated pneumonia (VAP) in the ICU, examiners expect fluency in severity scoring, antibiotic regimens, and culture interpretation. This comprehensive guide covers the complete pneumonia workup and management across all clinical settings.

CURB-65 Severity Scoring for CAP

The CURB-65 score rapidly stratifies pneumonia severity and guides site-of-care decisions:

Score Interpretation:

• CURB-65 = 0-1: Low risk (mortality <1%) → Outpatient management with oral antibiotics

• CURB-65 = 2: Intermediate risk (mortality 1-3%) → Consider admission or home IV; ensure close follow-up

• CURB-65 ≥3: High risk (mortality >3%) → Hospital admission, consider ICU if CURB-65 = 4-5

> Study Tip: CURB-65 scoring is tested on nearly every pneumonia CCS case. The StudyCCS question bank includes 20+ pneumonia cases where you must calculate CURB-65, justify admission decisions, and select appropriate antibiotics with real-time feedback.

Initial Workup: Labs and Cultures

Before initiating antibiotics:

Microbiologic Studies

• Blood cultures × 2 sets: (two separate needle sticks) Positive in 10-15% of CAP; guides narrowing of antibiotic coverage

• Respiratory specimen cultures:

◦ Sputum culture: Useful only if purulent; requires gram stain showing neutrophils and <10 epithelial cells

◦ Endotracheal aspirate: Standard for hospitalized/intubated patients

◦ Bronchoalveolar lavage (BAL): More specific but invasive; reserved for immunocompromised or unclear diagnosis

• Legionella and Mycoplasma testing: Indicated if atypical features (hyponatremia, GI symptoms, rash, slow-to-improve course)

• Urinary antigen testing: Legionella (high specificity; rapid) and Streptococcus pneumoniae (less commonly used)

Labs

• Complete blood count (CBC): WBC often elevated (mild leukocytosis common in CAP; profound elevation or left shift suggests more severe infection)

• Comprehensive metabolic panel (CMP): Assess BUN (CURB-65 criterion), glucose (hyperglycemia in infection), creatinine (renal function), electrolytes (hyponatremia seen with Legionella)

• Liver function tests: Not routine but assess if clinical concern for hepatic involvement

• Arterial blood gas (ABG) or pulse oximetry: If hypoxia suspected; assess oxygenation and acid-base status

• Procalcitonin and lactate: If concern for sepsis; lactate prognostic

Imaging

• Chest X-ray (CXR): Essential for diagnosis; assess pattern (lobar, bronchial, atypical), extent, complications (effusion, empyema, pneumothorax)

◦ Lobar consolidation: Classic for pneumococcal pneumonia

◦ Bilateral infiltrates: Suggest viral, atypical, or severe bacterial pneumonia

◦ Upper lobe cavitation: Think TB (especially if risk factors present)

• CT chest: Reserved for complications (empyema, abscess) or non-resolving pneumonia

Community-Acquired Pneumonia (CAP): Antibiotic Selection

Outpatient Management (CURB-65 0-1, able to tolerate oral antibiotics)

Empiric regimen for immunocompetent patients:

No comorbidities or risk factors:

• Amoxicillin 1 g TID × 7 days

OR

• Doxycycline 100 mg BID × 7 days

With comorbidities (COPD, smoking, recent antibiotics):

• Amoxicillin-clavulanate 875 mg BID × 7 days

OR

• Fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) × 5-7 days

Atypical pneumonia (Mycoplasma, Chlamydia) suspected (e.g., younger age, no consolidation on CXR):

• Azithromycin 500 mg daily × 3 days (Z-pack)

OR

• Doxycycline 100 mg BID × 7 days

Legionella risk (travel, water exposure, immunocompromised):

• Levofloxacin 750 mg daily × 5-7 days (preferred; achieves lung penetration)

OR

• Azithromycin 500 mg daily + Rifampin 600 mg BID

Inpatient Management (CURB-65 ≥2, respiratory failure risk)

Admitted to regular floor (not ICU):

Beta-lactam monotherapy or with macrolide:

• Ceftriaxone 1 g IV Q12H or cefotaxime 1 g IV Q8H

PLUS

• Azithromycin 500 mg IV/PO daily (covers atypical organisms)

OR

Fluoroquinolone monotherapy (if beta-lactam allergy or atypical concern):

• Levofloxacin 750 mg IV daily × 5-7 days

ICU Management (CURB-65 ≥4, septic shock, respiratory failure)

Combination therapy (broad-spectrum):

Regimen 1 (most common):

• Ceftriaxone 1-2 g IV Q12H or cefotaxime 1-2 g IV Q4-6H (or piperacillin-tazobactam 4.5 g IV Q6-8H)

PLUS

• Azithromycin 500 mg IV daily (covers atypical, may have immunomodulatory benefit)

PLUS

• Vancomycin 15-20 mg/kg IV Q8-12H (covers drug-resistant pneumococcus, MRSA; target trough 15-20 mcg/mL)

Regimen 2 (fluoroquinolone-based):

• Levofloxacin 750 mg IV daily

PLUS

• Vancomycin (as above) if MRSA risk (recent hospitalization, ICU stay, healthcare exposure)

Legionella or Mycoplasma risk:

• Replace azithromycin with moxifloxacin 400 mg IV daily (better atypical coverage than azithromycin in severe disease)

> Practice Alert: Antibiotic selection in pneumonia is one of the most frequently tested CCS topics. The StudyCCS question bank includes cases where you must justify empiric coverage, interpret culture results, and de-escalate appropriately—all critical CCS skills.

Healthcare-Associated Pneumonia (HCAP), HAP, and VAP

HCAP, HAP, and VAP (collectively nosocomial pneumonia) carry higher risk of multi-drug resistant (MDR) organisms and require broader empiric coverage.

Risk Factors for MDR Organisms

• Prior hospitalization or ICU admission

• Prolonged mechanical ventilation

• Recent broad-spectrum antibiotics

• Immunocompromised state

• Hemodialysis

Empiric Regimen for HAP/VAP (If No P. aeruginosa Risk)

Regimen 1 (most common):

• Ceftriaxone 1-2 g IV Q12H

PLUS

• Azithromycin 500 mg IV daily or Levofloxacin 750 mg IV daily

Regimen 2 (alternative):

• Piperacillin-tazobactam 4.5 g IV Q6-8H

Empiric Regimen for HAP/VAP with P. Aeruginosa Risk

Combination therapy:

• Piperacillin-tazobactam 4.5 g IV Q6H or Cefepime 1-2 g IV Q8-12H

PLUS

• Fluoroquinolone (Ciprofloxacin 400 mg IV Q8H or Levofloxacin 750 mg IV daily)

PLUS

• Vancomycin (if MRSA risk) or Aminoglycoside (gentamicin 5-7 mg/kg IV daily) for additional gram-negative coverage

Add antifungal (Fluconazole 400-600 mg IV daily) if:

• Prolonged ICU stay (>7 days)

• Recent antibiotics/steroid use

• Immunocompromised (HIV, transplant)

Specific Organisms and De-Escalation

Once culture results return (48-72 hours):

Atypical Pneumonia Deep Dive

Legionella Pneumophila

• Risk factors: Travel (hotels, cruise ships, water systems), immunocompromised

• Features: High fever, respiratory symptoms, GI symptoms (diarrhea, vomiting), neurologic symptoms (confusion), hyponatremia, elevated LFTs, CXR often shows bilateral infiltrates or lobar consolidation (can appear worse than clinical exam suggests)

• Diagnosis: Urinary antigen (rapid, 70-80% sensitive), culture (slow; requires special media)

• Treatment: Fluoroquinolone (levofloxacin 750 mg daily) is preferred; Azithromycin + Rifampin alternative

• Duration: 7-14 days (longer for immunocompromised or severe)

Mycoplasma Pneumoniae

• Risk factors: Younger patients, community outbreaks, lack of consolidation on CXR (atypical appearance)

• Features: Low-grade fever, dry cough, constitutional symptoms, cold agglutinin positivity (causes hemolysis), rash possible

• Diagnosis: Serology (acute and convalescent titers), PCR

• Treatment: Doxycycline, Azithromycin, or Fluoroquinolone

• Duration: 5-7 days

Chlamydia Pneumoniae

• Similar presentation to Mycoplasma

• Diagnosis: Serology, PCR

• Treatment: Doxycycline, Macrolides, or Fluoroquinolone

Aspiration Pneumonia Management

Occurs when oral secretions/gastric contents enter the airway. Risks include decreased level of consciousness, dysphagia, gastroesophageal reflux.

Likely organisms: Anaerobes (Peptostreptococcus, Prevotella, Fusobacterium), mixed gram-negatives

Empiric regimen:

• Ampicillin-sulbactam 3 g IV Q6H (covers anaerobes + gram-negatives)

OR

• Clindamycin 600 mg IV Q6-8H + Gentamicin 5-7 mg/kg IV daily (older approach, less used now)

OR

• Piperacillin-tazobactam 4.5 g IV Q6-8H

Duration: 7-14 days depending on severity

Prevention: NPO status if high aspiration risk, elevation of head of bed, swallow evaluation

Immunocompromised Host Pneumonia

HIV/AIDS (CD4 <200)

Opportunistic organisms:

• Pneumocystis jirovecii (PCP): Presents with gradual dyspnea, dry cough, exertional hypoxia, elevated LDH, normal or minimal CXR findings

◦ Diagnosis: Induced sputum or BAL with staining (Wright-Giemsa, Gram-Weigert)

◦ Treatment: Trimethoprim-sulfamethoxazole (TMP-SMX) 15-20 mg/kg/day IV (divided QID) × 21 days

◦ Adjunct: Corticosteroids if PaO2 <70 or A-a gradient >35 (improve outcomes)

◦ Prophylaxis: TMP-SMX single-strength daily if CD4 <200

• Mycobacterium avium complex (MAC): Usually CD4 <50; fever, GI symptoms, elevated LFTs

◦ Treatment: Azithromycin 1200 mg weekly + Ethambutol 15 mg/kg daily

◦ Prophylaxis: Azithromycin 1200 mg weekly if CD4 <50

• Cryptococcus neoformans: Meningitis common; pulmonary less frequent

◦ Diagnosis: Cryptococcal antigen, culture, CSF opening pressure

◦ Treatment: Amphotericin B ± Flucytosine, followed by Fluconazole

Chemotherapy/Neutropenic Patients

High risk for bacteria, fungi, viruses

Empiric:

• Piperacillin-tazobactam 4.5 g IV Q6H or Cefepime 2 g IV Q8-12H

PLUS

• Fluoroquinolone or Aminoglycoside (if pseudomonal coverage needed)

PLUS

• Amphotericin B or Fluconazole if prolonged neutropenia (>7 days)

Add Vancomycin if MRSA risk or hemodynamic instability

Repeat CXR and Monitoring for Treatment Response

Not all CXRs need repeat imaging.

Repeat CXR if:

• Clinical deterioration despite appropriate antibiotics (consider empyema, abscess, resistant organism)

• Immunocompromised patient

• No clinical improvement after 48-72 hours

• Concern for complications

Do NOT routinely repeat CXR if:

• Clinical improvement on day 3-5 of therapy

• Initial severity was mild (CURB-65 ≤1)

• Radiographic resolution lags clinical improvement by weeks

Expected timeline:

• Symptoms (fever, cough) improve days 2-3

• Hypoxia/respiratory status improves by day 5-7

• CXR infiltrates may persist 2-4 weeks even after clinical resolution

De-Escalation Strategy

Once culture results return (48-72 hours):

1. Narrow antibiotic spectrum based on susceptibilities

2. Switch to oral therapy once patient tolerating PO and clinically stable

3. Reduce duration: Most CAP 7 days; HAP/VAP 7-14 days depending on organism and severity

4. Stop unnecessary antibiotics: Remove antifungals, aminoglycosides if not needed

Example de-escalation:

• Empiric: Ceftriaxone + Azithromycin + Vancomycin

• Culture returns: Pneumococcus, sensitive to Penicillin

• De-escalate to: Amoxicillin 1 g PO TID × remaining days (total 7 days)

Complete Order Set for Pneumonia by Setting

Outpatient CAP (CURB-65 0-1, Discharged Home)

Imaging: CXR (confirm diagnosis, assess severity)

Labs: CBC, CMP, procalcitonin (optional)

Cultures: Blood cultures × 2, sputum culture (if productive)

Treatment: Amoxicillin 1 g TID OR Amoxicillin-clavulanate 875 mg BID × 7 days

Counseling: Return precautions (worsening dyspnea, high fever, altered mental status)

Follow-up: 48-72 hours telephone or visit to assess response

Inpatient CAP (CURB-65 2-3, Regular Floor)

Imaging: CXR, repeat in 48-72 hours if not improving

Labs: CBC, CMP, blood cultures × 2, sputum culture, procalcitonin, lactate

Treatment: Ceftriaxone 1 g IV Q12H + Azithromycin 500 mg IV daily × 5-7 days

De-escalate: Once cultures return based on susceptibilities

Monitoring: Daily I&Os, oxygen requirements, fever curve

Follow-up: Discharge on oral antibiotics; outpatient follow-up in 1-2 weeks

ICU Pneumonia/Septic Shock (CURB-65 4-5)

Imaging: CXR stat, portable; repeat as needed

Labs: CBC, CMP, blood cultures × 2, lactate, procalcitonin, ABG

Treatment: Ceftriaxone 1-2 g IV Q12H + Azithromycin 500 mg IV daily + Vancomycin 15-20 mg/kg Q8-12H

Consider: Vasopressors if SBP <65; ICU admission for monitoring, possible intubation

Repeat CXR: If deteriorating or ≥7 days to assess resolution

De-escalate: Once cultures, sensitivities return

HAP/VAP with P. Aeruginosa Risk

Imaging: CXR, repeat if not improving

Labs: Culture (blood, respiratory), CBC, CMP, lactate, procalcitonin

Treatment: Piperacillin-tazobactam 4.5 g IV Q6H + Levofloxacin 750 mg IV daily + Vancomycin (if MRSA risk)

Monitoring: Ventilator settings, sedation, daily spontaneous breathing trials (if intubated)

De-escalate: Once susceptibilities known

Infection control: Contact precautions if MRSA

2-Minute Screen

In the exam room, prioritize:

1. Assess severity (CURB-65): Confusion? Elevated BUN/RR? Hypotension? Age? Score guides admission

2. Order cultures BEFORE antibiotics: Blood × 2, sputum/BAL culture

3. CXR findings: Consolidation pattern guides organism (lobar = pneumococcus; atypical = Mycoplasma/Legionella)

4. Risk factors for MDR: Recent antibiotics, healthcare exposure, immunocompromised? → Broader coverage

5. Start empiric antibiotics AFTER cultures: Delay <4 hours in outpatient; <1 hour in ICU/sepsis

Don't-Miss Diagnoses

• Septic Shock: CURB-65 ≥4; requires ICU, vasopressors, aggressive management

• Empyema/Parapneumonic Effusion: Persistent fever despite antibiotics; requires thoracentesis, possible chest tube

• Lung Abscess: Cavitary lesion on imaging; anaerobic infection; prolonged antibiotics (3-4 weeks)

• Mycoplasma/Legionella: Atypical presentation; wrong antibiotics delay recovery

• PCP in AIDS: CD4 <200; can appear normal on CXR; elevated LDH; TMP-SMX + steroids improve outcomes

• Viral Pneumonia (Influenza, COVID-19): May superimpose bacterial infection; consider antivirals

Related Articles

• CCS Well-Child Visit: Pediatric Preventive Care Cases on Step 3

• CCS Acute Kidney Injury: Floor Management & Workup

• CCS Heart Failure: Acute Decompensation vs Chronic Management

Ready to practice? The StudyCCS question bank includes 28+ pneumonia cases covering CAP severity scoring, antibiotic selection across all settings, culture interpretation, and de-escalation with real-time grading. Master CURB-65, organ system complications, and resistant organisms today.